Category survey

Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer. Investments < €500k United States of America 2016    

Early imaging markers for elderly individuals with high risk to develop Alzheimers disease Investments < €500k United States of America 2016    

Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD Investments < €500k United States of America 2016    

Exploiting PrP for the diagnosis and treatment of protein aggregation diseases Investments < €500k United States of America 2016    

Neurotropic Viral Infection in CNS Aging and Alzheimers Disease Investments < €500k United States of America 2016    

Role of Circadian Clock Components in Apoptosis and Tauopathy in Drosophila Investments < €500k United States of America 2016    

Determining if Reduced Insulin Response in the Brain is Linked to Cognitive Loss Investments < €500k United States of America 2016    

Stress and Sexuality Divergent Neuropathy in Alzheimers Disease Investments < €500k United States of America 2016    

Brain Sleep Clearance of Amyloid-Beta Peptides Study (Brain SCRAPS) Investments < €500k United States of America 2016    

Function of the TREM2 R47H variant associated with risk of Alzheimers disease Investments < €500k United States of America 2016    

CD33 and Alzheimers Disease: from Biology to Therapy Investments < €500k United States of America 2016    

PDE4D Allosteric Modulators for Treating Cognitive Impairment Investments < €500k United States of America 2016    

Alzheimers Disease Viewed as a Neurovascular Inflammatory Disorder Investments < €500k United States of America 2016    

Biology of Down Syndrome: Impacts Across the Biomedical Spectrum Investments < €500k United States of America 2016    

International Cerebral Amyloid Angiopathy Conference in Boston Investments < €500k United States of America 2016    

EARLY DETECTION OF TAU ACETYLATION USING ULTRA-HIGH AFFINITY ANTIBODIES Investments < €500k United States of America 2016    

How Does APP Modulate Ferroportin? Developing Strategies to Determine Mechanism Investments < €500k United States of America 2016    

Humanizing Regulators of the Complement Cascade to Improve Research Relevance Investments < €500k United States of America 2016    

Multi-modal Prediction of Future Clinical Dementia Investments < €500k United States of America 2016    

Cerebral Microbleeds in Young Adults: risk factors, biomarkers and genetics Investments < €500k United States of America 2016    

Racial Disparities in Alzheimers Disease and Related Dementias: The Role of Blood Pressure Throughout Adulthood Investments < €500k United States of America 2016    

Cognitive and Neural Moderators of Longitudinal Decline in Frontotemporal Degeneration Investments < €500k United States of America 2016    

Treatment of randomly censored covariates in Alzheimers disease studies Investments < €500k United States of America 2016    

A longitudinal study of mid-to late-life blood pressure profiles as risk factors for Alzheimer´s disease in Hispanics Investments < €500k United States of America 2016    

Einstein Aging Study Investments < €500k United States of America 2016    

Brain Plasticity Measures in MCI Investments < €500k United States of America 2016    

Epigenetic Mechanisms in human memory quantified by non-invasive PET imaging Investments < €500k United States of America 2016    

Angiogenesis and Alzheimer’s Disease Investments < €500k United States of America 2016    

Assessment of Brain Insulin Resistance in Alzheimers Disease with Insulin Clamp Investments < €500k United States of America 2016    

Photoacoustic Microscopy of Metabolic Dysfunction in Alzheimer’s Disease Investments < €500k United States of America 2016    

An Innovative Approach to Study Alzheimer Disease Blood Biomarkers Investments < €500k United States of America 2016    

Developing, evaluating, and disseminating new methods and technologies to advance Parkinson disease research Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Cytohesins, ARF GTPases and Neurodegeneration Investments > €500k United States of America Motor neurone diseases 2016    

The role of aging in LRRK2-associated Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Blood RNA biomarkers of Parkinsons disease and progressive supranuclear palsy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Comprehensive Synaptome Proteomics Targeting Protein Expression and PTMs in HD Investments > €500k United States of America Huntington’s disease 2016    

Jamboxx: Interactive Respiratory Therapy through Music and Gaming Investments > €500k United States of America Motor neurone diseases 2016    

Contributions of mitochondrial fission proteins to mitophagy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Optimization and Validation of Improved Quantitative I-123 Brain SPECT Imaging Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Software Platform for Analyzing Alzheimers and Parkinsons fMRI Connectomes Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Identifying Huntingtons disease markers by modern statistical learning methods. Investments > €500k United States of America Huntington’s disease 2016    

Mechanisms of age-dependent nigral neuron loss in PINK1 knockout rats Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Repositioning Gliptins for Parkinsons Disease Treatment Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Synaptic Transmissions in the Basal Ganglia Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Preclinical testing of the splice modulating oligonucleotide LSP-GR1 Investments > €500k United States of America Motor neurone diseases 2016    

Exosome LRRK2 in Predicting Parkinson Disease Phenotypes Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Stress Granules and the Biology of TDP-43 Investments > €500k United States of America Motor neurone diseases 2016    

Small-Molecule Pharmacological Chaperones to Prevent Synuclein Transmission Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Analysis of the RNA-binding Protein FUS and Its Role in Neurodegenerative Disease Investments > €500k United States of America Motor neurone diseases 2016    

C9orf72 hexanucleotide repeat expansion caused neurodegeneration in ALS and FTD Investments > €500k United States of America Motor neurone diseases 2016